FindTrial
Sign In

Cizutamig

DRUG7 trials

Sponsors

Fraunhofer Institute For Translational Medicine And Pharmacology ITMP, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Candid Therapeutics, Ruijin Hospital

Conditions

Generalized Myasthenia GravisHealthy Participants StudyIgE Mediated Food AllergyIgE-Mediated Cow Milk AllergyIgE-Mediated HypersensitivityRheumatoid Arthritis (RA)SevereSystemic Lupus Erythematosus (SLE)

Early Phase 1

A Study of Cizutamig for Patients With Ulcerative Colitis
Not yet recruitingNCT07353450
Ruijin HospitalUlcerative Colitis (UC)
Start: 2026-01-01End: 2027-12-01Target: 15Updated: 2026-01-20

Phase 1

An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis
RecruitingNCT06946199
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyRheumatoid Arthritis (RA)
Start: 2025-06-23End: 2027-06-30Target: 28Updated: 2026-01-12
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
RecruitingNCT07215663
Candid TherapeuticsSystemic Lupus Erythematosus (SLE)
Start: 2025-09-04End: 2028-04-01Target: 47Updated: 2026-09-02
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
RecruitingNCT07215650
Candid TherapeuticsGeneralized Myasthenia Gravis
Start: 2025-09-16End: 2028-04-01Target: 44Updated: 2026-09-02
Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants
CompletedNCT07236411
Candid TherapeuticsHealthy Participants Study
Start: 2025-12-04End: 2026-07-14Updated: 2026-07-22
An open label, phase I/II study investigating the safety and efficacy of the bispecific T-cell engaging antibody cizutamig (BCMAxCD3) in patients with immune-mediated inflammatory diseases – the SPLENDID Trial
RecruitingCTIS2025-522857-20-00
Fraunhofer Institute For Translational Medicine And Pharmacology ITMPseropositive (anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor positive) rheumatoid arthritis (RA), Severe, treatment-refractory +3
Start: 2026-01-22Target: 12Updated: 2025-11-28
A Phase 1 Study of Cizutamig in IgE Mediated Diseases
WithdrawnNCT07408869
Candid TherapeuticsIgE-Mediated Cow Milk Allergy, IgE Mediated Food Allergy, IgE-Mediated Hypersensitivity
Start: 2026-04-01End: 2026-12-01Updated: 2026-07-22